Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI(R) (crizotinib)

DARMSTADT, Germany and NEW YORK, April 7, 2015 /PRNewswire/ —

Not intended for UK-based media 

  • In the second and third quarters of 2015, Merck and Pfizer will begin co-promoting XALKORI in the United States, Canada, Japan and five European Union countries (France, Germany, Italy, Spain and the United Kingdom) 
  • In the United States and Canada, XALKORI will be co-promoted by EMD Serono, the US and Canadian biopharmaceutical businesses of Merck  
  • Co-promotion of XALKORI allows the Merck-Pfizer alliance to establish a combined oncology sales organization in key markets for the program 

Merck and Pfizer today announced the finalization of the co-promotion agreement allowing the companies to jointly co-promote Pfizer’s anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib). This agreement showcases the alliance’s commitment to establishing a combined oncology sales organization in key markets in advance of the potential launch of avelumab*-based treatment regimens in the future.  

XALKORI is the first ALK inhibitor approved in the United States, Japan and the European Union (EU) and is supported by two positive global randomized trials in the first- and second-line ALK-positive advanced non-small cell lung cancer (NSCLC) treatment settings. To date, globally more than 8,000 patients have been treated with XALKORI, including those who received XALKORI in clinical trials.

Under the agreement, XALKORI will be co-promoted in two waves, the first of which will begin in the second and third quarters of 2015 in the United States, Canada, Japan and five European Union countries (France, Germany, Italy, Spain and the United Kingdom). In the United States and Canada, XALKORI will be co-promoted by EMD Serono, the US and Canadian biopharmaceutical businesses of Merck. The second wave will begin in 2016 and includes China and Turkey.  

In 2015, Merck will receive a reimbursement associated with its promotion of XALKORI, followed by an 80 percent (Pfizer), 20 percent (Merck) profit sharing on the product starting in 2016. The co-promotion term will last through December 31, 2020 for the United States, Canada, Japan, France, Germany, Italy, Spain and the United Kingdom and from January 1, 2016 through December 31, 2021 in China and Turkey. Pfizer will report the sales of XALKORI in countries where it is co-promoted with Merck.

“We are proud and excited to share the legacy of XALKORI, a medicine that changed the treatment paradigm for patients with ALK-positive metastatic NSCLC, with Merck,” said Liz Barrett, President and General Manager, Pfizer Oncology. “Through our co-promotion of XALKORI, we will establish a best-in-class global sales organization that will be exceptionally prepared for the potential launches of our future oncology medicines.”

“As we progress our robust program to co-develop and co-commercialize avelumab, the co-promotion agreement is an exciting milestone for the alliance between Merck and Pfizer, allowing us to establish our combined oncology sales organization in key markets for the program,” said Dr. Andrew Schiermeier, General Manager for the Merck-Pfizer Alliance and Head of Global Oncology, adding: “For Merck, this agreement is particularly important as it accelerates the establishment of our United States and Canada oncology sales organization ahead of our potential avelumab launches and positions us for future success in this market.”

This co-promotion relationship is related to the announcement in November 2014 of a global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab, an investigational anti-PD-L1 monoclonal antibody, to accelerate the development of immuno-oncology medicines for patients with cancer. The immuno-oncology alliance will also advance Pfizer’s PD-1 antibody.  

*Avelumab is the proposed International Nonproprietary Name (INN) for the anti-PD-L1 monoclonal antibody (MSB0010718C)

About Non-small Cell Lung Cancer 

Globally, lung cancer is the most common cause of cancer-related deaths in men and the second most common in women, responsible for almost twice as many deaths as both breast and prostate cancer combined[1]. Non-small cell lung cancer is the most common type of lung cancer, accounting for 85 to 90 percent of all lung cancers[2]. Locally advanced and metastatic disease account for approximately 35 to 40 percent[3 and 70 percent[4 of patients, respectively with NSCLC.

About XALKORI® (crizotinib) 

XALKORI is a kinase inhibitor indicated in the US for the treatment of patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The US indication is not limited to any specific line of therapy. In the EU, XALKORI is indicated for the treatment of adults with previously treated ALK-positive advanced NSCLC. XALKORI has received approval in more than 80 countries.  For more information and full prescribing information, please see: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002489/WC500134759.pdf.

Merck-Pfizer Alliance 

Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck.  The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The companies will collaborate on up to 20 high priority immuno-oncology clinical development programs, including combination trials, many of which are expected to commence in 2015.

Pfizer Inc.: Working together for a healthier world® 

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at http://www.pfizer.com.

Merck 

Merck of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Pfizer Disclosure Notice 

The information contained in this release is as of April 7, 2015. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. 

This release contains forward-looking information about an agreement between Pfizer and Merck to co-promote Pfizer’s XALKORI in certain markets as well as about the companies’ immuno-oncology alliance involving avelumab and Pfizer’s anti-PD-1 antibody and clinical development plans, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the success of the co-promotion arrangement and whether the companies will realize the anticipated benefits of the co-promotion arrangement; the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the possibility of unfavorable study results; risks associated with interim data, including the risk that the final results of the Phase I study for avelumab and/or additional clinical trials may be different from (including less favorable than) the interim data results and may not support further clinical development; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether and when drug applications may be filed in any jurisdictions for any potential product candidates or combination therapies; whether and when any such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of any of such product candidates or combination therapies; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at http://www.sec.gov and http://www.pfizer.com.

References 

  1. American Cancer Society. (2011). Global Facts & Figures Second Edition.  Retrieved from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf
  2. American Cancer Society. (2014). Lung Cancer (Non-Small Cell) [Fact sheet]. Retrieved from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf
  3. Blumenschein, G. R., Paulus, R., Curran, W. J., Robert, F., Fossella, F., Werner-Wasik, M., Herbst, R. S., Doescher, P. O., Choy, H., & Komaki, R. (2011). Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 17, 2312-2318.
  4. Wood, S. L., Pernemalm, M., Crosbie, P. A., & Whetton, A. D. (2013). The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer treatment reviews, 4,558-566.

Novogen Engages Leading US Investor Relations Firm

SYDNEY, April 2, 2015 /PRNewswire/ — Novogen Ltd (ASX:NRT NASDAQ:NVGN) today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company’s investor-awareness program in the US. PCG will be using their expertise in creating awareness and establishing key relationships within the US investment community via their targeted outreach campaign.

Dr Graham Kelly said: “The investment community has reacted positively in recent times to the Company’s extensive drug discovery program and with significant growth in activity ahead in the short-term, we felt it was timely to appoint an advisory firm to build on that momentum and communicate our activities to the market to maximise shareholder value.  Showcasing the Company to the wholesale investment community is a key part of our strategy to bring new investors into the stock through on-market buying. We look forward to working with the PCG team.”

Jeff Ramson, Founder and CEO of PCG stated, “We are excited to work with the entire team at Novogen.  We have extensive experience with Australian emerging growth companies that have stakeholders on several continents.  We look forward to communicating the Novogen story to a larger group of US investors, who need to learn about their drug technology platforms and how management will execute the Company’s strategy in the short and long term. We look forward to the partnership.”

ABOUT PCG ADVISORY GROUP

Founded in 2008, PCG Advisory Group is dedicated to the delivery of top tier capital markets advisory services, strategic investor relations, tactical digital and social media communications and cutting edge media and public relations for public and privately held companies. The team at PCG has extensive experience with life sciences and healthcare, high technology, metals and mining, financial services and emerging growth companies from around the globe.

PCG’s Capital Markets Advisory Services include overall investor relations’ strategy development to increase and leverage investor awareness, visibility and credibility. PCG’s Social and Digital Media services include leveraging social and professional digital media sites to effectively and accurately communicate client stories. As an aggregation, distribution, and engagement platform, PCG reaches thousands of individual, retail, institutional investors, bankers and analysts using proprietary techniques, search engine optimization, online marketing, website development and our proprietary and extensive distribution network. PCG’s Media and Public Relations services are a strategic and integral component of all Corporate Communications. The media and public relations team works with print, broadcast, online news sites and bloggers to communicate the best client story at the right time. PCG also actively assists clients during the pre- and post-IPO process as well as through mergers, acquisitions, uplistings, and or a potential crisis. Communicating the client’s story accurately and effectively is tantamount to maximizing exposure to its current and potential stakeholders.

About Novogen Limited

Novogen is a public, drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’).  The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs).  SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells.  The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubule drugs, result in comprehensive and fatal destruction of the cancer cell’s cytoskeleton.  Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our websites www.novogen.com

For more information please contact:

Corporate Contact

Dr. Graham Kelly

Executive Chairman & CEO

Novogen Group

Graham.Kelly@novogen.com           

+61 (0) 2 9472 4100

Media Enquiries

Cristyn Humphreys

Chief Operating Officer

Novogen Group

Cristyn.Humphreys@novogen.com

+61 (0) 2 9472 4111

Helsinn Group Signs Exclusive Agreement with Mundipharma for Distribution and Licence of Anamorelin in Mainland China, Hong Kong and Macao

This exclusive agreement broadens Helsinn’s existing partnerships for anamorelin in the area of cancer supportive care across multiple global territories

SINGAPORE, March 26, 2015 /PRNewswire/ — Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in Mainland China, Hong Kong and Macao.

Under the terms of the new agreement, Helsinn retains all international development as well as regulatory and clinical development activities and the supply of anamorelin for commercial use. Mundipharma will obtain the rights to marketing, promotion, distribution and sales of anamorelin in the designated territories.

Anamorelin is a novel, once-daily, orally active ghrelin receptor agonist under investigation for the treatment of Cancer Anorexia-Cachexia in patients suffering from non-small cell lung cancer (NSCLC), an area of significant unmet medical need. Cancer Anorexia-Cachexia is a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass, the inability to be fully reversed by conventional nutritional support and a progressive functional impairment[1].  In addition to its physical impact, Cancer Anorexia-Cachexia has also a marked psychological implication that contributes to decreased quality of life for both patients and their families[2]. By mimicking ghrelin, the so-called “hunger hormone” secreted by the gastrointestinal tract, anamorelin has been shown to improve lean body mass and appetite in NSCLC patients who are suffering from Cancer Anorexia-Cachexia.

The drug was also commented by the European Society for Medical Oncology (ESMO) in the “ESMO 2014 Wrap-Up: What should be remembered?” as one of the top innovations in oncology of 2014. The Guest Associate Editor mentioned that “The results from the phase III ROMANA 1 and 2 studies in NSCLC (1483O_PR) demonstrated significant benefits with anamorelin in body mass, body weight and patients’ symptoms and concerns about anorexia-cachexia. These findings suggest that anamorelin has the potential to improve the lives of a significant number of cancer patients.” [3], [4] 

Riccardo Braglia, CEO of Helsinn Group, said: “This partnership is another step in what we foresee as a long and successful collaboration with Mundipharma. We believe that anamorelin could be established as an important advancement in the management of cancer anorexia-cachexia. Anamorelin offers the potential for a new approach of treating this multifactorial clinical condition which can be devastating for patients and caregivers. Anamorelin has been shown in two large-scale clinical studies to improve lean body mass, potentially enabling patients to tolerate more treatments, and to alleviate their symptoms and concerns, ultimately helping them get more out of every day.”

Mr Raman Singh, President, Mundipharma Asia, Latin America, Middle East and Africa, said: “Improving the quality of patients’ lives has always been one of our core commitments, and the eventual launch of anamorelin in China seeks to provide healthcare professionals and patients with the effective support they need as patients undergo treatment. Our continued partnership with the Helsinn Group helps us further this goal, with their excellence in innovation and cancer supportive care.”

About anamorelin and ghrelin

Anamorelin HCl is an investigational selective, novel, orally active ghrelin receptor agonist that is under evaluation for the treatment of Cancer Anorexia-Cachexia in NSCLC patients. Ghrelin is an endogenous peptide secreted by the stomach. Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, lean body mass, appetite and metabolism.

Anamorelin is administered orally at 100mg, once daily. In phase II trials, anamorelin was shown to increase body weight compared with placebo and to improve patient-reported symptoms, including appetite. [5]

Anamorelin recently completed phase III trials (the ROMANA program) in NSCLC patients with cachexia. In ROMANA 1 and ROMANA 2, anamorelin increased, in respect to placebo, body weight, lean body mass, improved patients’ symptoms and concerns related to anorexia/cachexia and was generally well tolerated. [6]

About the Helsinn Group

Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the USA and a representative office in China. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.

Helsinn Group in-licenses early-to-late stage new chemical entities, completing their development by performing pre-clinical/clinical studies as well as associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn’s products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. Helsinn has built a large product portfolio of cancer care products with the alliance of around 70 global partners. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn’s products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers. Further information on Helsinn Group is available at www.helsinn.com.

About Mundipharma

Mundipharma’s global network of companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma provides patients across 6 continents with a growing portfolio of 19 products in 5 therapeutic areas, which include moderate-to-severe pain, consumer healthcare, oncology, respiratory disease, rheumatoid arthritis, antiseptics and laxatives. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients and to substantially improve their quality of life.

For more information, please visit: www.mundipharma.com.sg.

For more information please contact:

Helsinn Group

Paola Bonvicini
Head of Communication & Press Office
PH: +4191-985-21-21
info-hhc@helsinn.com

Mundipharma Pte Ltd

Stephenie Vasko
Head of Communications Asia Pacific, Middle East, Africa & Latin America
PH: +6563039732
stephenie.vasko@mundipharma.com.sg 

www.mundipharma.com.sg

[1] Fearon K et al., Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:48995

[2] Vaughan VC et al., Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle 2013;4:95109

[3] ESMO 2014. Anamorelin Shown to Improve Appetite and Body Mass in Patients with Cancer Anorexia-Cachexia. http://bit.ly/17fh0dE

[4] ESMO 2014 Wrap Up: What should be remembered? http://bit.ly/1Bu3oGu

[5] Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer. 2013;21(1):129137.

[6] Temel J, et al, Annals of Oncology, Volume 25, Supplement 4, 2014 (Abstract 1483O_PR)

Logo – http://photos.prnasia.com/prnh/20150302/8521501264LOGO

So Klose Successfully Achieves ISO 9001:2008 Recertification

Asia’s first matchmaking and dating service to achieve ISO9001:2008 certification

HONG KONG, March 26, 2015 /PRNewswire/ — So Klose is proud to announce that its service team successfully passed the second ISO9001:2008 QMS recertification audit with zero non-conformities in end-2014 which was certified by SGS, first within the industry in Asia.

So Klose has been an ISO9001:2008 certified matchmaking and dating services company since 2011 and was recertified in December 2014 with zero non-conformities

So Klose has been an ISO9001:2008 certified matchmaking and dating services company since 2011 and was recertified in December 2014 with zero non-conformities

 

Created in 2009, today the multi-award-winning So Klose upscale dating and matchmaking agency offers services for single executives, professionals and entrepreneurs in the Chinese community.

The recent audit examined So Klose’s business practices and internal management procedures to ensure they meet international quality standards and customer requirements. The audit also examined processes for continuous improvement in customer satisfaction, procedural control, training and internal communications with an overall customer satisfaction rate of over 96%. This is So Klose’s second ISO certification.

ISO 9001:2008 is based on a number of quality management principles including a strong customer focus, the motivation and implication of top management, the process approach and continual improvement, establishment of clear policies, planning and implementation, resource management and efficient process control.

“Obtaining the renewed ISO:9001 certificate strengthens our reputation as a trustworthy service provider and assures our present and prospective clients that our quality is beyond standard in the marketplace,” says Carolyn Chan, Director of So Klose. “External certification of our quality management system is an independent validation of So Klose’s commitment to quality. It provides an invaluable edge in the matchmaking and dating services sector and offers an accredited approach to deliver quality services, improves our business processes and expands our business opportunities.

ABOUT SO KLOSE

So Klose® is providing matchmaking, dating, and personal introduction services to single elites. Most of the members are well-educated, high-income earners, executives working overseas, professionals, and entrepreneurs.

The majority of its members (97%) hold university degrees; about half of the male members and female members have studied abroad. So Klose® has received first-time industry awards, such as: “The Most Reliable Dating and Matchmaking Services Company” at Hong Kong’s Most Valuable Companies Awards 2014; the “China’s Top Ten Model Brands in Matchmaking, Dating and Personal Introduction Services”; “16th Tao Heung Innovative Entrepreneur Award”; “2011 Hong Kong Emerging Service Brand”; the ISO9001:2008 QMS certification, first within the industry in Asia, and the “Intellectual Capital Management Excellence Award”, as well as the “national matchmaking consultant” qualification awarded by the Ministry of Human Resources and Social Security of China, and the “Executive Member” and “Certified Matchmaker” qualifications awarded by the Matchmaking Institute of New York, USA.

More information about SO KLOSE.COM is available at http://www.so-klose.com.

Photo – http://photos.prnasia.com/prnh/20150324/8521501859
Logo – http://www.prnasia.com/sa/2011/12/05/20111205150300103459-l.jpg

Sigma-Aldrich Announces Exclusive Distribution Agreement with Roche

– Provides Researchers with Global Access to Roche Biochemical Reagents Product Portfolio

ST. LOUIS, March 19, 2015 /PRNewswire/ — Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and Technology company, announced today it signed an exclusive global distribution agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). The agreement pairs Roche’s high-quality Biochemical Reagents product portfolio with the industry-leading eCommerce and supply chain capabilities of Sigma-Aldrich.

Under the agreement, Sigma-Aldrich will employ its sales, marketing and eCommerce expertise, and leverage the strength of its relationships with the scientific community, to present and distribute the Roche Biochemical Reagents product portfolio, which includes kits and enzymes for cellular analysis, proteomics and conventional PCR applications. For more information, visit www.sigma-aldrich.com/roche.

“Sigma-Aldrich is excited to offer the global scientific community access to Roche’s leading portfolio of scientific tools and reagents. The addition of these life science tools supports our strategy to augment our portfolio with products that accelerate customer scientific research programs,” said Eric Green, Executive Vice President and President, Sigma-Aldrich Research. “We look forward to working with Roche in this relationship.”

“This agreement allows us to provide more customers with access to high-quality Roche Biochemical Reagent products through Sigma-Aldrich’s expanded eCommerce and distribution networks,” said Paul Brown, Head of Roche Molecular Diagnostics. “In addition, this will provide us the flexibility to devote more resources to our primary focus areas.”

Transition of the Roche portfolio to Sigma-Aldrich is expected to take place in 2015. In the interim, these products will continue to be available through existing Roche channels. For more information, visit the Roche or Sigma-Aldrich websites.

©2015 Sigma-Aldrich Co. LLC. All rights reserved. Sigma-Aldrich and SAFC are trademarks of Sigma-Aldrich Co. LLC or its affiliates, registered in the U.S. and other countries.

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co. LLC., registered in the US and other countries.

Heraeus enters agreement to acquire NeoMetrics

ST. PAUL, Minnesota and PLYMOUTH, Minnesota, March 19, 2015 /PRNewswire/ — Heraeus Medical Components, a global business unit of Heraeus Holding GmbH, has executed a share purchase agreement to acquire 100% of the stock in NeoMetrics.  NeoMetrics, headquartered in Plymouth, Minnesota, specializes in designing and manufacturing guidewires and components for medical devices.  The company’s production facilities, in both Minnesota and Costa Rica, include cleanroom manufacturing and extensive guidewire fabrication technologies.  Closing of this transaction is expected to occur in the next 60 days.

“With this acquisition, Heraeus Medical Components will add new interventional technologies to augment their leadership position as a sourcing solution for the world’s medical device companies. We are excited about the potential growth opportunities within the interventional field,” said Dr. Nicolas Guggenheim, President of Heraeus Medical Components.  “NeoMetrics’ experience in the development of interventional and vascular access guidewires substantially builds upon our existing component capabilities.  We plan to use our combined expertise to bring new solutions for our medical device customers.”

“We are excited to become part of Heraeus Medical Components,” said Dave Liebl, President, NeoMetrics.  “Joining Heraeus will allow us to support our continued growth, including the opportunity to introduce our products and expertise to new markets.  Both companies share a culture of consistently exceeding customer expectations.”

The management team and employees of NeoMetrics will continue as part of Heraeus, contributing important domain expertise and ensuring continuity for customers.  Gene Champeau, co-founder and CEO of NeoMetrics will assist Heraeus in developing new business platforms and product strategies on a consulting basis. Heraeus intends to continue operation of both of the NeoMetrics facilities post-closing.

About NeoMetrics
NeoMetrics, headquartered in Plymouth, Minnesota, is a private company that was founded in 2001.  The company operates exclusively as an OEM partner of medical device companies. They specialize in designing, manufacturing and securing Regulatory clearance for interventional and vascular access guidewires. 

About Heraeus
Heraeus Medical Components is a global business unit of Heraeus Holding GmbH. Heraeus, the technology group headquartered in Hanau, Germany, is a global, private company with more than 160 years of tradition. We create high value solutions for our customers, strengthening their competitiveness for the long term. Our fields of competence include precious metals, materials and technologies, sensors, biomaterials and medical products, quartz glass, and specialty light sources.

In fiscal year 2013, Heraeus achieved product revenue of €3.6 billion and precious metals trading revenue of €13.5 billion. With some 12,500 employees in over 110 subsidiaries worldwide, Heraeus holds a leading position in its global markets.

Cerner To Integrate Patient-Generated Data Using Validic Digital Health Platform

DURHAM, North Carolina, March 12, 2015 /PRNewswire/ — Validic, the health care industry’s leading digital health platform, announced today an alignment with health information technology supplier Cerner Corp. to enable their access and connectivity to patient-generated data from clinical and fitness devices and applications.

Photo – http://photos.prnewswire.com/prnh/20150311/181102
Logo – http://photos.prnewswire.com/prnh/20150311/181101LOGO

Cerner is a global leader in health information technologies that connect people, information and systems at more than 18,000 facilities worldwide. Recognized for its technology innovation, Cerner solutions assist clinicians in making care decisions and enable organizations to manage the health of populations.

Using Validic’s digital health platform, Cerner will be able to integrate clinical, fitness, wellness and nutritional data into the patient’s personal health portal, HealtheLife℠. With the patient’s consent, that information will be sent to their electronic medical record, giving nurses and physicians visibility to their health on a daily basis. This access to actionable, patient-generated data continues Cerner’s focus and commitment to offering a suite of solutions that support personalized health care and enables individuals and populations to improve their overall health.

“Cerner is committed to working with our clients to create a future where the health care system works to improve the well-being of individuals and communities. To be successful, it is critical to provide access to actionable data on a regular basis, not just what’s collected when someone goes to the doctor,” said Brian Carter, senior director and general manager, personal health, Cerner. “Given Validic is device- and platform-agnostic, our alignment provides a much broader reach to clinical and wellness data to help propel our digital health strategy to health care organizations we serve, including the acceleration of remote patient monitoring, telehealth, and wellness initiatives.”

“Cerner’s innovative technologies connect people and systems around the world within and outside of the provider setting,” said Ryan Beckland, CEO and co-founder, Validic. “In working with Cerner, Validic bridges the data gap among its health care stakeholders and the clinical devices, fitness wearables, and patient applications they need to provide actionable insights and in-depth patient engagement. Working with a leader like Cerner, we are able to help deliver its connected health strategies into the hands of clients, and help fuel the exciting industry transformation to more accountable, value-based health care delivery.”  

Validic provides solutions for a broad range of health care segments, including health systems and providers, pharmaceutical groups, research organizations and employer groups. Validic’s clients continue to rely on Validic to help them integrate and manage the world of mobile health and clinical devices, wearables and applications. With one easy connection to Validic, these health care organizations are able to access actionable patient data. This enables health care companies to gain valuable insights allowing them to work to improve care treatment plans, better population management and engagement, and enable improved connectivity across the entire continuum of care.

In the current health care environment, many companies are trying to solve the problem of integrating, managing and updating connections to the rapidly expanding ecosystem of mobile health technologies. Validic has helped its clients overcome this challenge by successfully delivering secure, standardized and actionable data for integration into clients’ health technology systems, electronic medical records, patient engagement portals, and wellness applications.

About Cerner

Cerner‘s health information technologies connect people, information and systems at more than 18,000 facilities worldwide. Recognized for innovation, Cerner solutions assist clinicians in making care decisions and enable organizations to manage the health of populations. The company also offers an integrated clinical and financial system to help health care organizations manage revenue, as well as a wide range of services to support clients’ clinical, financial and operational needs. Cerner’s mission is to contribute to the improvement of health care delivery and the health of communities.  On February 2, 2015, Cerner Corporation acquired substantially all of the assets, and assumed certain liabilities, of the Siemens Health Services business from Siemens AG.  Nasdaq: CERN. For more information about Cerner, visit cerner.com, read our blog at cerner.com/blog, connect with us on Twitter at twitter.com/cerner and on Facebook at facebook.com/cerner.

Certain trademarks, service marks and logos set forth herein are property of Cerner Corporation and/or its subsidiaries. All other non-Cerner marks are the property of their respective owners.

About Validic  

Validic is the healthcare industry’s leading cloud-based, digital health platform for convenient and quick access to patient data from in-home clinical devices, wearables and patient healthcare applications. By connecting its growing base of customers — that includes providers, pharmaceutical companies, payers, wellness companies and health IT vendors — to the continuously expanding list of digital health technologies, Validic enables healthcare companies to better coordinate care across their communities, improve their patient engagement strategies and more efficiently manage their patient populations. Validic’s innovative, scalable and FDA Class I MDDS technology delivers actionable, standardized and HIPAA-compliant consumer health data from the best in-class mobile health devices and applications. Validic was recently recognized by Gartner and received Frost & Sullivan’s Best Practices and Best Value in Healthcare Information Interoperability award. Validic’s leading global mobile health ecosystem reaches over 100 million lives and continues to grow daily. To learn more about Validic, follow Validic on Twitter at @validic or visit www.validic.com.

Media Contact

Media Contact

Validic – Ashley Needham

Cerner Corp. – Marlene Bentley

+1-919-423-0233

+1-816-225-9772

ashley.needham@validic.com

marlene.bentley@cerner.com

Norgine and Arc Medical Announce Partnership for Endoscopic Device, ENDOCUFF VISION™

LONDON, March 12, 2015 /PRNewswire/ —

Norgine and Arc Medical Design Ltd. today announced a partnership that will see Norgine commercialising and distributing ENDOCUFF VISION, a Class 1 sterile medical device used in colonoscopy, across a number of major European markets, Australia and New Zealand. Norgine’s first launch of ENDOCUFF VISION™  will take place in the UK Q2 2015.

     (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )

ENDOCUFF VISION™  is a single use, sterile endoscopic overtube, which fits onto the distal end of most endoscopes, and has been designed to improve tip control during extubation and enhance mucosal vision in patients with diseases of the colon, including colorectal cancer. The improved visualisation of lesions has been shown to result in an increase in both the Adenoma Detection Rate (ADR) and Mean Adenomas per Patient (MAP) rate.[1],[2],[3],[4]

Colorectal cancer is the second most common cause of cancer-related mortality in the world[5]; nearly 1.4 million new cases of colorectal cancer were diagnosed worldwide in 2012 and 412,000 people are diagnosed with it every year in Europe.[6],[7]

Peter Stein, Chief Executive Officer Norgine, commented, “We are excited about our new partnership with Arc Medical and the promotion of ENDOCUFF VISION, a device which not only leads to a significant increase in lesion detection, but also ensures a quality colonoscopy and avoids the need for repeat procedures – thus significantly improving the patient experience. This partnership is a further example of Norgine’s commitment to improving quality in colonoscopy and adds to our existing bowel cleansing portfolio.”

References 

  1. Biecker E, et al. Novel Endocuff-assisted colonoscopy significantly increases the polyp detection rate. A randomized controlled trial. J Clin Gastroenterol. 2014;00:000-000 
  2. Floer M, et al. Higher adenoma detection rate with Endocuff assisted colonoscopy. Plos One. 3 December 2014; 10.1371 
  3. Lenze F, et al. Endocuff-assisted colonoscopy: a new accessory to improve adenoma detection rate? Technical aspects and first clinical experiences. Endoscopy. 2014; 46(7):610-614 
  4. Marsano J, et al. Endocuff assisted colonoscopy increases adenoma detection rate: A multicentre study. ASGE Posters, 10095, DDW, Chicago 2014 
  5. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al.  Cancer incidence and mortality patterns in Europe:  Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-14037. Zavoral M et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915 
  6. Colorectal Cancer Statistics, World Cancer Research Fund International, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/colorectal-cancer-statistics [Accessed 4 March 2015]
  7. Zavoral M et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915

See release on http://www.norgine.com

Charlotte Andrews +44(0)7714-061-485
Isabelle Jouin : Mob: +44(0)7714-406372

Making the Old New Again — Blazblue Takes a Bold Approach

GUANGZHOU, China, March 4, 2015 /PRNewswire/ — 37Games, a global browser and mobile game publisher and developer, recently acquired the publish rights of Blazblue Revolution Reburning (BBRR) of Mainland China. The game’s idea is based on a worldwide famous fighting game title Blazblue, which is originally developed by Arc System Works (Yokohama, Japan).

In Mainland China, there are two directions in which developers can choose to take upon acquiring licenses from outside firms. The first option is to simply incorporate the characters, story lines, and artwork into an existing game engine. Using the framework from existing games can keep costs low for the developer and is considerably less risky than using an all-new game engine or design. Players will already be familiar with the mechanics of the game, so it is basically a simple matter of re-skinning the game and telling a different story.

A more risky approach some developers would take is to acquire the related licenses and then develop a completely new game from the ground up.

Blazblue Revolution Reburning (BBRR), a Japanese style fighting game for the mobile market, is a recent example of a game that was built from the ground up using purchased license.

91Act, a mobile game developer, get the related licenses from Arc System Works and re-developed the game from zero, then grant the Operation Right of BBRR in Mainland to 37Games.

So far, the more risky approach seems to be paying off. BBRR has already been nominated as the “Most Anticipated Game” by Baidu Mobile Games. BBRR has even garnered some celebrity attention. Two well-known celebrities have agreed to fight in the game. The loser will have to embarrassedly support a garment according to the winner’s choice.

As China is poised to be the world’s largest entertainment market, the future seems to be bright for those foreign firms who are willing to share their licenses with capable developers and publishers. The number of current online users in China surpasses previous records and the surge is expected continue in coming years. It is likely for more to seize this opportunity looking ahead.

Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore

— New system for fast, precise radiotherapy and radiosurgery now ready for clinical use

SINGAPORE, March 2, 2015 /PRNewswire/ — Mount Elizabeth Novena Hospital will soon become the first treatment center in Singapore to treat cancer using the TrueBeam™ STx system for radiotherapy and radiosurgery from Varian Medical Systems (NYSE:VAR). At a Grand Opening event last Friday, clinicians introduced the new system, which enables advanced forms of treatment including radiosurgery, a precise method of using carefully shaped high-energy radiation beams to attack a tumor from outside the body, without performing surgery.

“We are scheduled to deliver our first patient treatment this week,” said Dr. Lee Kuo Ann, MBBS, FRCR, FAMS, consultant radiation oncologist at Mount Elizabeth Novena. “The TrueBeam system will enable us to deliver large doses to tumors with great precision. We’ll be able to treat many inoperable brain tumors, tumors that are close to the spinal cord, and tumors of the lung, liver, or pancreas, which are subject to respiratory motion during treatment. The system includes gating technology that can enhance precision by compensating for that kind of tumor motion.”

About the TrueBeam STx System
The TrueBeam STx system was designed to treat tumors with tremendous accuracy and speed. The system incorporates numerous technical innovations that dynamically synchronize advanced imaging, patient positioning, motion management, and treatment delivery during a radiotherapy or radiosurgery procedure in order to target tumors precisely. TrueBeam STx has been designed to advance the treatment of lung, breast, intracranial, prostate, head and neck, and other types of cancer.

With its High Intensity Mode, TrueBeam STx can accurately deliver high doses more than twice as fast as earlier generations of technology. It incorporates a unique high-resolution beam shaping device that shapes the treatment beam so that it matches the three-dimensional shape of the targeted tumor, minimizing the impact on surrounding healthy tissues.

“With gating, the High Intensity Mode, and imaging technologies, we will be able to minimize the impact of treatment on healthy tissues,” said Dr. Lee. “For example, during breast cancer treatments we can reduce the radiation going to the heart and lungs.”

“Varian’s mission is to help save millions of lives around the world every year. We are pleased and honored that the outstanding clinical team at Mount Elizabeth Novena Hospital will be working to save lives using Varian’s advanced technology for treating cancer,” said Jean-Luc Devleeschauwer, president for the Asia-Pacific (APAC) region for Varian’s Oncology Systems business.

Note to editors: High resolution images of Varian’s TrueBeam system for image-guided radiotherapy are available online at this URL: http://varian.mediaroom.com/index.php?s=31899&cat=2470&mode=gallery.

ABOUT VARIAN MEDICAL SYSTEMS
Varian Medical Systems, Inc., of Palo Alto, California, is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications. Varian Medical Systems employs approximately 5,900 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

ABOUT MOUNT ELIZABETH NOVENA HOSPITAL
Mount Elizabeth Novena Hospital, Parkway Pantai Group’s new hospital in the heart of Singapore’s premier medical hub in Novena, opened in July 2012. The modern all single-bedded room hospital sets new benchmarks for quality healthcare to reinforce Singapore’s reputation for delivering world-class medical services to both local and foreign patients. Adopting global best-practice standards for quality patient care as well as clinical outcomes, Mount Elizabeth Novena Hospital caters to the continuing demand for high quality and competitively priced healthcare services in Singapore and around the world. For more information, please visit the website at http://mountelizabethnovena.com.

FOR INFORMATION CONTACT:

UNITED STATES

ASIA

Meryl Ginsberg

Kevin Lo

Tel: +1.650.424.6444

Tel: +852.6039.9115

meryl.ginsberg@varian.com

kevin.lo@varian.com